{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-147583","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.436031+00:00","generated_at":"2026-06-01T07:57:26.097970+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Agios sells vorasidenib royalty rights to Royalty Pharma for $905M upfront upon FDA approval","bullets":["Royalty Pharma pays $905M to Agios upon FDA approval of vorasidenib (PDUFA date Aug 20, 2024).","Agios retains $200M milestone from Servier upon approval; total potential cash inflow of ~$1.1B.","Royalty Pharma receives 15% royalty on first $1B annual US sales; Agios retains 3% on sales above $1B.","Proceeds intended to fund PYRUKYND launches in thalassemia/sickle cell and expand pipeline.","Transaction closing requires FDA approval by Oct 31, 2024 and other customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-147583","json":"https://secwatch.observer/filing/0001193125-24-147583.json","markdown":"https://secwatch.observer/filing/0001193125-24-147583.md","text":"https://secwatch.observer/filing/0001193125-24-147583.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312524147583/0001193125-24-147583-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312524147583/d717537d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:57:26.097970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}